

**Quarterly Project Update Report: Clinical Trial Data Platform (CTDP) - Q1 2024**

---

**Executive Summary**

As of Q1 2024, the Clinical Trial Data Platform (CTDP) project is progressing steadily through its Testing phase. The team has successfully completed foundational work and is now focusing on validation to ensure the platform's reliability and robustness. While progress is commendable, some challenges such as integration issues with legacy systems are impacting timelines slightly. However, these obstacles are being managed effectively through regular stakeholder meetings and contingency planning.

**Key Milestones Achieved**

- **Core Modules Setup:** 100% of core modules have been successfully set up.
- **Validation Testing:** 75% of validation tests have been completed with no failures observed.
- **User Interface (UI) Testing:** 60% of UI components are operational and functional.

**Current Risks and Blockers**

- **Integration Issues:** Challenges in aligning the CTDP with existing systems are causing minor delays. These are being addressed through targeted testing and vendor collaboration.
- **Resource Constraints:** Limited initial team size is affecting project timelines, but remote work arrangements are maintaining productivity.

**Next Quarter Objectives**

In Q2 2024, the focus will be on full system testing to ensure all functionalities operate smoothly. Key objectives include:
- Conducting comprehensive performance testing and load testing.
- Finalizing advanced analytics modules before year-end.
- Providing training to senior staff for effective platform utilization.

**Resource and Budget Overview**

Budget usage is on track with slight increases due to additional testing resources. Staffing remains adequate, utilizing a core team plus remote contributors. Vendor collaboration is underway to address any resource gaps identified during the Testing phase.

---

This report reflects MediNova Pharmaceuticals' commitment to overcoming challenges and ensuring timely project completion. Ongoing efforts are focused on refining the platform for deployment in Q2 2024.